Previous close | 81.48 |
Open | 81.84 |
Bid | 78.99 x 100 |
Ask | 79.17 x 200 |
Day's range | 78.67 - 81.84 |
52-week range | 50.20 - 92.87 |
Volume | |
Avg. volume | 829,041 |
Market cap | 5.483B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 12.06 |
EPS (TTM) | 6.56 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 104.90 |
LAUR, ESLT and LNTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 21, 2024.
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The
Lantheus Holdings' (NASDAQ:LNTH) stock is up by a considerable 37% over the past three months. Given the company's...